Treatment of congenital cytomegalovirus beyond the neonatal period: an observational study
- 11 January 2020
- journal article
- research article
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 179 (5) , 807-812
Abstract
Recently, valganciclovir treatment of symptomatic congenital cytomegalovirus (cCMV) disease, commenced during the neonatal period (≤ 4 weeks), was found to improve hearing and developmental outcome. However, many children (symptomatic or asymptomatic at birth) present only after 4 weeks of age. The purpose of this observational retrospective study was to describe the outcome and safety of valganciclovir therapy in infants with cCMV who started treatment > 4 weeks of life. Of the 91children who started antiviral treatment > 4 weeks of age, 66/298 (22.2%) were symptomatic at birth; 25/217 (11.5%) were asymptomatic at birth. Treatment was initiated on average at 14 weeks of age (range 5–77 weeks) and at 53.3 weeks (range 12–156 weeks), respectively. Of the 45 affected ears in the symptomatic group, 30 (66.7%) improved and only 2 (4.4%) deteriorated, with most of the improved ears (27/30, 90%) returning to normal. In the asymptomatic group, late-onset treatment was initiated and out of the 42 deteriorated ears, 38 (90.5%) improved after at least 1 year of follow-up. Hematological adverse events, i.e., neutropenia, were noted in a minority of cases (4.4%). Conclusion: Our study demonstrates the benefits and safety aspects of treating symptomatic and asymptomatic children with cCMV even beyond the recommended neonatal period. What is Known: • Valganciclovir treatment of symptomatic congenital cytomegalovirus (cCMV) disease, commenced during the neonatal period, is beneficial in improving hearing and developmental outcome. • However, data of treatment started beyond the neonatal period is lacking. What is New: • Our study demonstrates the benefits of treating symptomatic children with cCMV as well as asymptomatic children that develop late-onset hearing loss even beyond the recommended neonatal period. • This was true for symptomatic children who presented > 4 weeks as well as to those were asymptomatic at birth but experienced late hearing deterioration.Keywords
This publication has 13 references indexed in Scilit:
- Hearing in Children with Congenital Cytomegalovirus Infection: Results of a Longitudinal StudyThe Journal of Pediatrics, 2016
- Clinical Implications for Children Born With Congenital Cytomegalovirus Infection Following a Negative AmniocentesisClinical Infectious Diseases, 2016
- Hearing outcome of infants with congenital cytomegalovirus and hearing impairmentArchives of Disease in Childhood, 2016
- Valganciclovir for Symptomatic Congenital Cytomegalovirus DiseaseNew England Journal of Medicine, 2015
- Treatment of Late-Onset Hearing Loss in Infants With Congenital Cytomegalovirus InfectionClinical Pediatrics, 2013
- Treatment of symptomatic congenital cytomegalovirus infection beyond the neonatal periodJournal of Clinical Virology, 2012
- Oral valganciclovir treatment for congenital cytomegalovirus infectionPediatrics International, 2011
- Congenital cytomegalovirus infection: treatment, sequelae and follow-upThe Journal of Maternal-Fetal & Neonatal Medicine, 2010
- Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trialThe Journal of Pediatrics, 2003
- Longitudinal Investigation of Hearing Disorders in Children with Congenital CytomegalovirusJournal of the American Academy of Audiology, 2000